放射性医薬品の世界市場展望

◆英語タイトル:Global Radiopharmaceuticals Market Outlook 2020
◆商品コード:KUIK60810
◆発行会社(調査会社):KuicK Research
◆発行日:2016年4月
◆ページ数:600
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,200 ⇒換算¥244,200見積依頼/購入/質問フォーム
Multi UserUSD4,400 ⇒換算¥488,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body’s functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly.The global radiopharmaceuticals market is dominated by the North American region followed by the European region. Owing to the production of Mo-99 by the Canada and continuous research activities in different clinical institutes in USA such as National Cancer Institute, the North American market is headed for a strong growth in the future. Other markets in the Asia-Pacific region are also expected to show a significant growth in the future, with China, India, Japan, South Korea, Brazil, and South Africa being the most promising and potential regions. The major driver of growth in these countries is the domestic production of isotopes by reactors coupled with supportive government initiatives.
The radiopharmaceuticals market can be segmented into diagnostic & therapeutic radiopharmaceuticals. Close to 90% of the global radiopharmaceuticals market is dominated by diagnostic segment wherein SPECT accounts for major market share. The SPECT market is dominated by Tc-99m isotopes and F-18 accounts for majority of share in PET segment.
“Global Radiopharmaceuticals Market Outlook 2020” Report Highlight:
• Global Radiopharmaceutical Market Overview
• Global Radiopharmaceuticals Market Dynamics
• FDA & EMA Guidelines for Radiopharmaceuticals
• Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
• Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
• Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
• Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals

【レポートの目次】

1. Global Radiopharmaceutical Market Overview
1.1 Current Market Scenario
1.2 Diagnostic & Therapeutic Radiopharmaceuticals
1.3 Global Radiopharmaceticals Clinical Pipeline Overview

2. Global Radiopharmaceuticals Market Dynamics

3. Radioisotopes Used in Radiopharmaceuticals

4. EMA Guidelines for Radiopharmaceuticals
4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products
4.2 Toxicological & Pharmacological Tests
4.3 Clinical Documentation
4.4 Radiation Dosimetry
4.5 Labelling & Packaging

5. FDA Guidelines for Radiopharmaceuticals
5.1 Clinical Indication
5.2 General Considerations for Safety Assessments
5.3 Clinical Evaluation of Medical Imaging Agents

6. Canada Guidelines for Radiopharmaceuticals
6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research
6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans
6.3 Stability Testing of Existing Drug Substances and Products
6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)

7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration

8. Marketed Radiopharmaceuticals Clinical Insight by Indication
8.1 Florbetapir F 18 (Amyvid)
8.2 Iobenguane I-123 (AdreView)
8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
8.4 Radium-223 Chloride (Alpharadin & Xofigo)
8.5 Tc 99m Tilmanocept (Lymphoseek)
8.6 Florbetaben F18 (NeuraCeq)
8.7 Capromab (ProstaScint)
8.8 Pentetreotide (Oktreotid & 111In)
8.9 Iodine I 131 Derlotuximab Biotin (Cotara)
8.10 Tc 99m Besilesomab (Scintimun)
8.11 Samarium 153 lexidronam (Quadramet)
8.12 Technetium Tc 99m Sulfur Colloid Injection
8.13 Tc 99m Apcitide (AcuTect)
8.14 DW 166HC (Milican)
8.15 Tc 99m Sulesomab (LeukoScan)
8.16 Satumomab (OncoScint CR/OV)
8.17 Pentetreotide (OctreoScan & SomatoTher)
8.18 Tc 99m ior cea1
8.19 Tc 99m Nofetumomab Merpentan (VerLuma)

9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended

10. Competitive Landscape
10.1 Avid Radiopharmaceuticals
10.2 Actinium Pharmaceuticals
10.3 AREVA Med
10.4 Bayer HealthCare Pharmaceuticals
10.5 Cardinal Health
10.6 Immunomedics
10.7 Lantheus Medical Imaging
10.8 Merck
10.9 Navidea
10.10 Nordion
10.11 Lantheus Medical Imaging
10.12 GE Healthcare
10.13 Ion Beam Applications
10.14 PETNET Solutions (Siemens Healthcare Global)

Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2014-2020
Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2014 & 2020
Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2014 - 2020
Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2014-2020
Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2014 & 2020
Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2014 - 2020
Figure 1-7: Global Radiopharmceutical Pipeline by Phase (%), 2016
Figure 1-8: Global Radiopharmceutical Pipeline by Phase (Numbers), 2016
Figure 1-9: Suspended & Discontinued Radiopharmceutical Pipeline (%), 2016
Figure 1-10: Suspended & Discontinued Radiopharmceutical Pipeline (Number), 2016
Figure 8-1: Lantheus Medical Imaging Product Pipeline


Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug
Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug
Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug
Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug
Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug
Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug
Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug
Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug
Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug
Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug
Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug
Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug
Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug
Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug
Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug
Table 1-16: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug
Table 1-17: Iron-59 Investigation Properties as Radiopharmaceuticals Drug
Table 1-18: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug
Table 1-19: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug
Table 1-20: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug
Table 1-21: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug
Table 1-22: Radium-223 Investigation Properties as Radiopharmaceuticals Drug
Table 1-23: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug
Table 1-24: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug
Table 1-25: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug
Table 1-26: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug
Table 1-27: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug
Table 1-28: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug
Table 1-29: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug
Table 1-30: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug
Table 1-31: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug
Table 1-32: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug


【レポートのキーワード】

放射性医薬品

★調査レポート[放射性医薬品の世界市場展望]販売に関する免責事項
★調査レポート[放射性医薬品の世界市場展望]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆